Tuberculosis (TB) is a contagious and airborne infectious disease caused by bacteria called Mycobacterium tuberculosis. It typically affects the lungs but can also affect other parts of the body. Tuberculosis vaccines help in developing immunity against the tuberculosis disease. The major tuberculosis vaccines available in the market are: BCG, VPM1002, MVA85A, and DAR-901. BCG vaccine is the only licensed tuberculosis vaccine which provides protection against severe forms of TB in children. However, its efficacy in preventing pulmonary TB in adults is limited. Due to this limitation, there is strong support from governments and non-profit organizations for funding innovative vaccine research.

The global tuberculosis vaccine market is estimated to be valued at US$ 149.67 Mn in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One of the key drivers for the growth of the tuberculosis vaccine market is strong government support for developing innovative vaccines with higher efficacy. For instance, in 2021, the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded a grant of US$ 37.7 million to Aeras, a non-profit organization, for supporting the development of novel TB vaccines. Besides direct funding, governments are also taking initiatives to fast-track regulatory approvals and purchase commitments for effective vaccines. This will encourage private investments in TB vaccine R&D. Increased funding and initiatives by governments and organizations are expected to significantly contribute to the discovery and commercialization of new tuberculosis vaccines.

High global TB disease burden particularly in developing regions also presents a major growth opportunity for the market. According to WHO, over 10 million people fell ill with TB in 2021, of which 5.5 million were men, 3.3 million were women and 1.1 million were children. As available vaccines have limited efficacy against pulmonary TB, there is an urgent need for effective vaccines which will reduce the burden of disease in developing economies. New vaccines can potentially prevent millions of new TB cases annually worldwide.

Segment Analysis
The tuberculosis vaccine market is dominated by the intradermal BCG subsegment owing to the wide uptake of BCG vaccines, which is the only approved tuberculosis vaccine as of now. BCG vaccines account for over 95% of the global tuberculosis vaccine market share. The BCG vaccines are administered through intradermal route to induce protective immunity against severe forms of tuberculosis in children.

PEST Analysis
Political: Governments across different countries are focusing on prevention and control of tuberculosis through vaccination programs. Public private partnerships are being formed to boost research and development for novel and efficacious vaccines.
Economic: Growing disease burden of tuberculosis globally has raised economic costs of treatment and control measures. This has ramped up investments in vaccine development from pharmaceutical companies looking to tap market opportunities.
Social: Heightened awareness about tuberculosis and availability of preventive measures has increased the demand for vaccination, especially in high prevalence regions.
Technological: Advancements in immunology and vaccine platforms like recombinant BCG vaccines, prime-boost strategies, etc. are expediting clinical trials of new tuberculosis vaccine candidates.

Key Takeaways
The global tuberculosis vaccine market share is expected to witness high growth over the forecast period of 2023 to 2030 supported by rising disease incidence, growing focus on immunization, and rapid pipeline progression of novel vaccines.

Regional analysis: Asia Pacific currently dominates the market and is expected to maintain its lead position owing to the large patient pool of tuberculosis in countries like India and China. South East Asian countries will be the fastest growing regional market.

Key players: Key players operating in the tuberculosis vaccine market are Fujitsu Limited, Mindtree Limited, IBM Corporation, Wipro Limited, Unisys Corporation, CenturyLink Inc., Virtustream Inc. and HCL Technologies Limited. These players are involved in collaborations and partnerships to accelerate research and development efforts

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it